Bruce S. Fischer

1.8k citations

22 papers · 574 indexed · h-index 11

Co-authors: Arlene O. Siefker‐Radtke Padmanee Sharma Abdel Saci Paolo A. Ascierto Jonathan E. Rosenberg Kristoffer Staal Rohrberg José A. López-Martín S. Meadows–Shropshire
Topics: Bladder and Urothelial Cancer Treatments (5 papers)Cancer Immunotherapy and Biomarkers (4 papers)Lung Cancer Treatments and Mutations (4 papers)
Cited by: Oncology Surgery Sensory Systems
Journals: Journal of Clinical OncologySHILAP Revista de lepidopterologíaBlood
Partner nations: United States Germany Spain

In The Last Decade

Bruce S. Fischer

22 papers receiving 566 citations

Peers

Countries citing papers authored by Bruce S. Fischer

Since Specialization

Citations

This map shows the geographic impact of Bruce S. Fischer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bruce S. Fischer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bruce S. Fischer more than expected).

Fields of papers citing papers by Bruce S. Fischer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bruce S. Fischer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bruce S. Fischer. The network helps show where Bruce S. Fischer may publish in the future.

Co-authorship network of co-authors of Bruce S. Fischer

This figure shows the co-authorship network connecting the top 25 collaborators of Bruce S. Fischer. A scholar is included among the top collaborators of Bruce S. Fischer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bruce S. Fischer. Bruce S. Fischer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	1664TiP A phase II randomized study of BMS-986012, an anti-fucosyl-GM1 monoclonal antibody, plus carboplatin, etoposide, and nivolumab (NIVO) as first-line (1L) therapy in patients with extensive-stage small cell lung cancer (ES-SCLC) 2021 ·Annals of Oncology ·Quincy S. Chu,Kaushal Parikh,Luis Paz‐Ares,Alejandro Navarro,B. Markman,(unknown),Georgia Kollia,Chao He,Kinjal Sanghavi,Chang Han,Bruce S. Fischer,Udayan Guha,(unknown),(unknown),(unknown),Neal Ready	2
2	393 First-in-human phase 1/2a study of the novel nonfucosylated anti–CTLA-4 monoclonal antibody BMS-986218 ± nivolumab in advanced solid tumors: initial phase 1 results 2020 ·SHILAP Revista de lepidopterología ·Claire F. Friedman,Paolo A. Ascierto,Diwakar Davar,Mark H. O’Hara,Ronnie Shapira‐Frommer,Matthew C. Dallos,Vivek Khemka,(unknown),Bruce S. Fischer,(unknown),Li Li,(unknown),Palanikumar Ravindran,Ke Xu,Georgia Kollia,(unknown),(unknown),(unknown),Martin Gutierrez	5
3	A phase II, randomized study of nivolumab (NIVO), NIVO plus linrodostat mesylate, or NIVO plus intravesical bacillus Calmette-Guerin (BCG) in BCG-unresponsive, high-risk, nonmuscle invasive bladder cancer (NMIBC): CheckMate 9UT. 2020 ·Journal of Clinical Oncology ·Noah M. Hahn,Sam S. Chang,Maxwell V. Meng,Neal D. Shore,Badrinath R. Konety,Gary D. Steinberg,Juergen E. Gschwend,Hiroyuki Nishiyama,Joan Palou,John A. Taylor,Alexandre Lambert,Li Zhu,Toshiki Maeda,(unknown),Bruce S. Fischer,Chandrika Jeyamohan,Dimitrios Zardavas,Fred Witjes	9
4	Nivolumab Alone and With Ipilimumab in Previously Treated Metastatic Urothelial Carcinoma: CheckMate 032 Nivolumab 1 mg/kg Plus Ipilimumab 3 mg/kg Expansion Cohort Results 2019 ·Journal of Clinical Oncology ·Padmanee Sharma,Arlene O. Siefker‐Radtke,Filippo de Braud,Umberto Basso,Emiliano Calvo,Petri Bono,Michael A. Morse,Paolo A. Ascierto,José A. López-Martín,Peter Brossart,Kristoffer Staal Rohrberg,Begoña Mellado,Bruce S. Fischer,S. Meadows–Shropshire,Abdel Saci,Margaret K. Callahan,Jonathan E. Rosenberg	178
5	Fibroblast Growth Factor Receptor 3 Alterations and Response to PD-1/PD-L1 Blockade in Patients with Metastatic Urothelial Cancer 2019 ·European Urology ·Li Wang,Yixuan Gong,Abdel Saci,Péter M. Szabó,Alberto Martini,Andrea Necchi,Arlene O. Siefker‐Radtke,Sumanta K. Pal,Elizabeth R. Plimack,John P. Sfakianos,Nina Bhardwaj,Amir Horowitz,Adam M. Farkas,David J. Mulholland,Bruce S. Fischer,William Oh,Padmanee Sharma,Jun Zhu,Matthew D. Galsky	89
6	A phase II, randomized study of nivolumab (nivo) or nivo plus BMS-986205 with or without intravesical Bacillus Calmette-Guerin (BCG) in BCG-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC): CheckMate 9UT. 2019 ·Journal of Clinical Oncology ·Noah M. Hahn,Sam S. Chang,Maxwell V. Meng,Neal D. Shore,Badrinath R. Konety,Gary D. Steinberg,Juergen E. Gschwend,Hiroyuki Nishiyama,Juan Palou Redorta,John A. Taylor,Ayanbola Elegbe,Alexandre Lambert,Li Zhu,Yuko Ishii,Toshiki Maeda,(unknown),Gary D. Grossfeld,Bruce S. Fischer,Mark Rutstein,Alfred Witjes	8
7	A multi-arm phase I dose escalating study of an oral NOTCH inhibitor BMS-986115 in patients with advanced solid tumours 2018 ·Investigational New Drugs ·Kyaw Aung,Anthony B. El-Khoueiry,Karen A. Gelmon,Ben Tran,Gaurav Bajaj,Bing He,Tian Chen,Li Zhu,(unknown),Shashwati Basak,Zhenhao Qi,Anna Spreafico,Bruce S. Fischer,Jayesh Desai	32
8	Fibroblast growth factor receptor 3 (FGFR3), peroxisome proliferator-activated receptor gamma (PPARg), and outcomes with nivolumab (nivo) in metastatic urothelial cancer (UC). 2018 ·Journal of Clinical Oncology ·Matt D. Galsky,Abdel Saci,Péter M. Szabó,Li Wang,Jun Zhu,Alex Azrilevich,Bruce S. Fischer,Andrea Necchi,Arlene O. Siefker‐Radtke,Padmanee Sharma	6
9	A phase I study of AL101, a pan-NOTCH inhibitor, in patients (pts) with locally advanced or metastatic solid tumors. 2018 ·Journal of Clinical Oncology ·Anthony B. El-Khoueiry,Jayesh Desai,Swaminathan P. Iyer,Shirish M. Gadgeel,Suresh S. Ramalingam,Leora Horn,Patricia LoRusso,Gaurav Bajaj,Georgia Kollia,Zhenhao Qi,Shashwati Basak,Bruce S. Fischer,Matti Davis,Philippe L. Bédard	20
10	Gamma Secretase Inhibition by BMS-906024 Enhances Efficacy of Paclitaxel in Lung Adenocarcinoma 2017 ·Molecular Cancer Therapeutics ·Katherine M. Morgan,Bruce S. Fischer,Francis Y. Lee,(unknown),Joseph R. Bertino,Jeffrey Rosenfeld,(unknown),Hossein Khiabanian,Sharon R. Pine	51
11	The Safety and Activity of BMS-906024, a Gamma Secretase Inhibitor (GSI) with Anti-Notch Activity, in Patients with Relapsed T-Cell Acute Lymphoblastic Leukemia (T-ALL): Initial Results of a Phase 1 Trial 2014 ·Blood ·Patrick A. Zweidler‐McKay,Daniel J. DeAngelo,Dan Douer,Hervé Dombret,Oliver G. Ottmann,Norbert Vey,Deborah A. Thomas,Li Zhu,Fei Huang,Gaurav Bajaj,Bruce S. Fischer	40
12	The effects of liver impairment on the pharmacokinetics of brivanib, a dual inhibitor of fibroblast growth factor receptor and vascular endothelial growth factor receptor tyrosine kinases 2013 ·Cancer Chemotherapy and Pharmacology ·Anthony B. El-Khoueiry,James Posey,(unknown),Smitha Krishnamurthi,S. Syed,Georgia Kollia,Ian Walters,Bruce S. Fischer,Eric Masson	3
13	Lack of food effect on single-dose pharmacokinetics of brivanib, and safety and efficacy following multiple doses in subjects with advanced or metastatic solid tumors 2011 ·Cancer Chemotherapy and Pharmacology ·Patricia LoRusso,Geoffrey I. Shapiro,Herbert I. Hurwitz,Mary Jo Pilat,(unknown),Georgia Kollia,S. Syed,Bruce S. Fischer,Eric Masson	2
14	A Phase I Study of An Oral Hedgehog Pathway Antagonist, BMS-833923, in Patients with Relapsed or Refractory Multiple Myeloma, 2011 ·Blood ·Carol Ann Huff,Swaminathan P. Iyer,Kevin R. Kelly,George Somlo,Luis H. Camacho,Jeffrey A. Zonder,Bruce S. Fischer,Lixin Lang,Steven Zhang,(unknown),Kelly L. Bennett	8
15	Metabolism, Excretion, and Pharmacokinetics of Oral Brivanib in Patients with Advanced or Metastatic Solid Tumors 2010 ·Drug Metabolism and Disposition ·Tarek Mekhail,Eric Masson,Bruce S. Fischer,Jiachang Gong,Ramaswamy A. Iyer,Jinping Gan,Janice Pursley,(unknown),(unknown),Ram Ganapathi	21
16	*JAK2V617F patients with essential thrombocythemia present with clinical features of polycythemia vera 2008 ·Leukemia & lymphoma* ·Sujiang Zhang,(unknown),Bruce S. Fischer,(unknown),(unknown),Xuemei Sun,Wei Xu,Jianyong Li	10
17	Phase II open-label study to investigate efficacy and safety of PTK787/ZK 222584 (PTK/ZK) orally administered once daily or twice daily at 1,250 mg as second-line monotherapy in patients (pts) with stage IIIB/IV non-small cell lung cancer (NSCLC) 2007 ·Journal of Clinical Oncology ·Thomas Gauler,Benjamin Besse,Jean‐Baptiste Méric,V. Gounant,Bruce S. Fischer,Tobias R. Overbeck,Heiko Krissel,Dirk Laurent,Jean‐Charles Soria,Wilfried Eberhardt	25
18	Phase II open-label study to investigate efficacy and safety of PTK787/ZK 222584 orally administered once daily at 1,250 mg as second-line monotherapy in patients (pts) with stage IIIB or stage IV non-small cell lung cancer (NSCLC) 2006 ·Journal of Clinical Oncology ·Thomas Gauler,Bruce S. Fischer,Jean‐Charles Soria,V. Gounant,Frank Griesinger,Heiko Krissel,Dirk Laurent,Wilfried Eberhardt	12
19	Capsaicin Inhibits Jurkat T-Cell Activation by Blocking Calcium Entry Current ICRAC 2001 ·Journal of Pharmacology and Experimental Therapeutics ·Bruce S. Fischer,(unknown),(unknown),Thomas V. McDonald	37
20	An Overriding Radius Fracture in a Child with an Intact Ulna: Management Considerations 1985 ·Orthopedics ·(unknown),Bruce S. Fischer	3

About Bruce S. Fischer

Bruce S. Fischer is a scholar working on Oncology, Biological Psychiatry and Behavioral Neuroscience, having authored 22 papers that have together received 574 indexed citations. Recurring topics across this work include Bladder and Urothelial Cancer Treatments (5 papers), Cancer Immunotherapy and Biomarkers (4 papers) and Lung Cancer Treatments and Mutations (4 papers). The work is most often cited by research in Oncology (290 citations), Surgery (235 citations) and Sensory Systems (23 citations). Bruce S. Fischer has collaborated with scholars based in United States, Germany and Spain. Frequent co-authors include Arlene O. Siefker‐Radtke, Padmanee Sharma, Abdel Saci, Paolo A. Ascierto, Jonathan E. Rosenberg, Kristoffer Staal Rohrberg, José A. López-Martín, S. Meadows–Shropshire, Margaret K. Callahan and Filippo de Braud. Their work appears in journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact